I-MAB
Company Profile
Business description
I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will likely be eftansomatropin, a long-acting growth hormone that has a large market in China among pediatric patients with short stature, which we estimate will launch in 2024 or 2025. Other core assets include lemzoparlimab, a potential best-in-class CD47 inhibitor in phase 2 trials; uliledlimab, a potential best-in-class CD73 inhibitor in phase 2 trials; and felzartamab for the Chinese market, a CD38 inhibitor for multiple myeloma, which could have a phase 3 data readout in 2023.
Contact
555 West Haiyang Road
55th Floor, New Bund Center
Pudong District
Shanghai 200124
CHNT: +86 2160578000
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2024
Employees
220
I-MAB News & Analysis
stocks
10 of the cheapest US stocks of 2022
Morningstar Investment Ideas
Stocks
ETFs
- Australian ETFs
- Active Australian Equity ETFs
- Passive Australian Equity ETFs
- Emerging Market Equity ETFs
- Sustainable ETFs
- Active Global Equity ETFs
- Passive Global Equity ETFs
- Active Australian Fixed Interest ETFs
- Passive Australian Fixed Interest ETFs
- Active Australian Listed Property ETFs
- Passive Australian Listed Property ETFs
- Active Global Fixed Interest ETFs
- Passive Global Fixed Interest ETFs
- Active Global Infrastructure ETFs
- Passive Global Infrastructure ETFs
- Active Global Property ETFs
- Passive Global Property ETFs
Funds
- Active Australian Equity Funds
- Passive Australian Equity Funds
- Active Global Equity Funds
- Passive Global Equity Funds
- Sustainable Funds
- Emerging Market Equity Funds
- Passive Australian Listed Property Funds
- Active Australian Listed Property Funds
- Passive Global Infrastructure Funds
- Active Global Infrastructure Funds
- Active Global Property Funds
- Passive Global Property Funds
- Active Australian Fixed Interest Funds
- Passive Australian Fixed Interest Funds
- Active Global Fixed Interest Funds
- Passive Global Fixed Interest Funds
Markets
Index
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| All Ordinaries | 7,893.80 | 44.40 | 0.57% |
| CAC 40 | 7,914.65 | 70.28 | -0.88% |
| DAX 40 | 17,896.50 | 35.67 | -0.20% |
| Dow JONES (US) | 38,225.66 | 322.37 | 0.85% |
| FTSE 100 | 8,172.15 | 50.91 | 0.63% |
| HKSE | 18,413.79 | 206.66 | 1.14% |
| NASDAQ | 15,840.96 | 235.48 | 1.51% |
| Nikkei 225 | 38,236.07 | 37.98 | -0.10% |
| NZX 50 Index | 11,916.42 | 42.38 | 0.36% |
| S&P 500 | 5,064.20 | 45.81 | 0.91% |
| S&P/ASX 200 | 7,624.40 | 37.40 | 0.49% |
| SSE Composite Index | 3,104.82 | 8.22 | -0.26% |
Market Movers
Name
|
Last price
|
Change
|
% Change
|
|---|---|---|---|
| Red 5 Ltd RED | 0.43 | 0.01 | -1.16% |
| Sayona Mining Ltd SYA | 0.03 | 0.00 | 3.13% |
| Telstra Group Ltd TLS | 3.58 | 0.01 | -0.28% |
| Pilbara Minerals Ltd PLS | 4.19 | 0.13 | 3.08% |
| Capitol Health Ltd CAJ | 0.25 | 0.01 | 2.08% |
| South32 Ltd S32 | 3.59 | 0.04 | 1.13% |
| Evolution Mining Ltd EVN | 3.76 | 0.20 | -4.94% |
| The Star Entertainment Group Ltd SGR | 0.43 | 0.02 | 4.27% |
| Imugene Ltd IMU | 0.08 | 0.00 | -1.76% |
| Zip Co Ltd ZIP | 1.30 | 0.06 | 4.84% |